Connect with us

Business

CSL open to new manufacturing options after AstraZeneca production – Sydney Morning Herald

The biotech giant says it can hit the 50 million dose mark by December and is in talks with the government about how else it can help fight the pandemic.

Published

on

Article feature image

Biotech giant CSL is in talks with the government about its longer-term role in Australias fight against coronavirus, as the company races to complete 50 million doses of the AstraZeneca vaccine by December.
The $123 billion blood plasma giant confirmed over the weekend that it was now producing more than 1 million doses of the vaccine per week, with more than 3.7 million doses released to the public by the end of April. There is a four-week quality control and approvals process that must be completed…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
Atlassian’s Scott Farquhar tells founders not to bootstrap – The Australian Financial Review
Australia’s trust in big banks up 19% in just 2 years: report